A strong uptick in doctor prescriptions and coverage from health insurers is being credited for solid quarterly revenues for GW Pharmaceuticals. The London-based firm... Losses narrow for GW Pharmaceuticals on dramatic revenue increase

A strong uptick in doctor prescriptions and coverage from health insurers is being credited for solid quarterly revenues for GW Pharmaceuticals.

The London-based firm that makes cannabis-derived CBD medicines reported revenue of $91 million for the third quarter ended Sept. 30, up more than 3,500% from the same period a year ago.

Despite the revenue growth, the company lost roughly $13.8 million last quarter, or 4 cents a share. That was an improvement from the third quarter of 2018, when GW Pharmaceuticals lost nearly $80 million.

Sales for the quarter exceeded analyst expectations, which were $85.6 million.

GW Pharmaceuticals’ trademark CBD medication for rare types of epilepsy, Epidiolex, won approval in September for sale in the European Union.

The company is also researching cannabis-derived medications to treat tuberous sclerosis complex, a genetic disorder, and Rett syndrome, a rare neurological disease.

The company’s shares are traded on the Nasdaq under the ticker symbol GWPH.

For more details on the company’s quarterly results, click here.

A chart displaying the earnings for some hemp companies is available here.

Subscribe to our Newsletter

MJ Shareholders avatar

MJ Shareholders

MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers

No comments so far.

Be first to leave comment below.




( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )